Antengene inks clinical collaboration with MSD to evaluate ATG 037 in combo with Keytruda in patients with locally advanced or metastatic solid tumours

Antengene Corporation Limited, a leading commercial-stage innovative, global biopharmaceutical company, announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) on a multicenter, open-label, phase I dose-finding study of ATG-037 as a monotherapy and in combination with MSD